IMPURITIES AVAILABLE FOR 'Cediranib'

Omsynth Lifesciences Pvt. Ltd. is one of the leading manufacturer and exporter of Cediranib. Cediranib is an oral small-molecule tyrosine kinase inhibitor (TKI) that selectively targets vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3). By blocking these receptors, it inhibits angiogenesis, thereby restricting blood supply to tumors and suppressing their growth. Cediranib also exhibits activity against c-Kit and platelet-derived growth factor receptors (PDGFRs), broadening its anti-angiogenic effects. It has been investigated in the treatment of various solid tumors, including ovarian cancer, colorectal cancer, and glioblastoma. The drug is usually administered orally once daily, with dose adjustments based on tolerance. Common side effects include hypertension, fatigue, diarrhea, nausea, and anorexia. Serious adverse effects may involve thromboembolic events, bleeding, or impaired wound healing. While not widely approved, cediranib continues to be studied in clinical trials for its potential role in advanced cancer therapy. Buy high quality Cediranib from Omsynth Lifesciences.